Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lorlatinib for Crizotinib-Pretreated ROS1-Positive NSCLC
NCT03439215Phase 2Unknown
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Jun 2017
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
A Phase 2 trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Status: unknown.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03439215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439215.